- Molecular NameAlmotriptan
- Synonymalmotriptan
- Weight335.472
- Drugbank_IDDB00918
- ACS_NO154323-57-6
- Show 3D model
- LogP (experiment)1.87
- LogP (predicted, AB/LogP v2.0)2.68
- pkaN/A
- LogD (pH=7, predicted)1.04
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-1.39
- LogSw (predicted, AB/LogsW2.0)0.16
- Sw (mg/ml) (predicted, ACD/Labs)0.1
- No.of HBond Donors1
- No.of HBond Acceptors5
- No.of Rotatable Bonds6
- TPSA64.79
- StatusFDA approved
- AdministrationN/A
- PharmacologyA triptan drug discovered and developed by Almirall for the treatment of migraine headache.
- Absorption_value75.0
- Absorption (description)Almotriptan is well absorbed after oral administration
- Caco_2N/A
- Bioavailability70.0
- Protein binding35.0
- Volume of distribution (VD)249 L
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmMetabolised in the liver by monoamine oxidase and cytochrome P450 isoenzymes (CYP3A4 and CYP2D6). Metabolites are inactive.
- Half life3~4 h
- ExcretionIt is eliminated by a number of pathways and 40 to 50% of a dose is recovered unchanged in urine.
- Urinary ExcretionN/A
- Clerance26.6 L/h.
- ToxicityThe most common adverse events during treatment with AXERT? were nausea, somnolence, headache, paresthesia, and dry mouth.
- LD50 (rat)N/A
- LD50 (mouse)N/A